Abstract
Resistance to the novel β-lactam/β-lactamase inhibitor combination ceftazidime-avibactam (CAZ-AVI) among carbapenem-resistant Enterobacteriaceae (CRE) has infrequently been reported in the United States. We report unexpectedly high rates of resistance to CAZ-AVI in CRE bloodstream isolates at our institution associated with the nonoutbreak spread of New Delhi metallo-β-lactamase in diverse Enterobacteriaceae species.
Keywords:
CRE; NDM; bacteremia; carbapenemase; ceftazidime-avibactam.
© The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail [email protected].
MeSH terms
-
Adult
-
Aged
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use*
-
Azabicyclo Compounds / pharmacology
-
Azabicyclo Compounds / therapeutic use*
-
Bacteremia* / drug therapy
-
Bacteremia* / epidemiology
-
Bacteremia* / microbiology
-
Cancer Care Facilities
-
Ceftazidime / pharmacology
-
Ceftazidime / therapeutic use*
-
Child, Preschool
-
Drug Combinations
-
Drug Resistance, Bacterial
-
Enterobacteriaceae Infections* / drug therapy
-
Enterobacteriaceae Infections* / epidemiology
-
Enterobacteriaceae Infections* / microbiology
-
Enterobacteriaceae* / drug effects
-
Enterobacteriaceae* / enzymology
-
Enterobacteriaceae* / genetics
-
Female
-
Humans
-
Male
-
Middle Aged
-
Young Adult
-
beta-Lactamases
Substances
-
Anti-Bacterial Agents
-
Azabicyclo Compounds
-
Drug Combinations
-
avibactam, ceftazidime drug combination
-
Ceftazidime
-
beta-Lactamases
-
beta-lactamase NDM-1